Fri, Dec 19, 2014, 11:13 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • mousemouse595 mousemouse595 Aug 31, 2012 9:41 AM Flag

    CEO clearly lied here is the proof

    He said multiple offers but failed to release anything public which means he got no offers

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • CEO did not lie in June,2011 in his comments to Bloomberg.The offers were closer to 15 than 30.
      Read the statement carefully.
      Now--in June,2011, Amarin had
      1) No patents
      2) Vascepa was not approved
      3) Anchor 3 trial data for 200-500mg polulation was NOT available--This is a big opportunity.
      4) Reduce-It study costing 120 mil.$ was not launched.
      How can PFE or AZN or others offer price over 20 in May,2011?
      Facts now are better--that is why 8 analysts--are estimating Value between 21.50 to 28$/share.
      What is missing?
      approval for 200-500mg.trigl.population--expected by Aug.2013
      Sales for Vascepa
      Based on Lipitor analogy from 1996-99,Vascepa is in 1996 stage.
      1997-98 provided sales data,bidding followed in 1999.
      Price offered -90 bil.$ in 1999 was 3 times what Pfizer was willing to offer in 1996.

      Sentiment: Strong Buy

 
AMRN
1.13+0.08(+7.62%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.